Tags

Type your tag names separated by a space and hit enter

Cannabinoid receptors as therapeutic targets.
Annu Rev Pharmacol Toxicol 2006; 46:101-22AR

Abstract

CB1 and CB2 cannabinoid receptors are the primary targets of endogenous cannabinoids (endocannabinoids). These G protein-coupled receptors play an important role in many processes, including metabolic regulation, craving, pain, anxiety, bone growth, and immune function. Cannabinoid receptors can be engaged directly by agonists or antagonists, or indirectly by manipulating endocannabinoid metabolism. In the past several years, it has become apparent from preclinical studies that therapies either directly or indirectly influencing cannabinoid receptors might be clinically useful. This review considers the components of the endocannabinoid system and discusses some of the most promising endocannabinoid-based therapies.

Authors+Show Affiliations

Department of Anesthesiology and Physiology, University of Washington School of Medicine, Seattle, WA 98195-6540, USA. kmackie@u.washington.edu

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

16402900

Citation

Mackie, Ken. "Cannabinoid Receptors as Therapeutic Targets." Annual Review of Pharmacology and Toxicology, vol. 46, 2006, pp. 101-22.
Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006;46:101-22.
Mackie, K. (2006). Cannabinoid receptors as therapeutic targets. Annual Review of Pharmacology and Toxicology, 46, pp. 101-22.
Mackie K. Cannabinoid Receptors as Therapeutic Targets. Annu Rev Pharmacol Toxicol. 2006;46:101-22. PubMed PMID: 16402900.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid receptors as therapeutic targets. A1 - Mackie,Ken, PY - 2006/1/13/pubmed PY - 2006/4/13/medline PY - 2006/1/13/entrez SP - 101 EP - 22 JF - Annual review of pharmacology and toxicology JO - Annu. Rev. Pharmacol. Toxicol. VL - 46 N2 - CB1 and CB2 cannabinoid receptors are the primary targets of endogenous cannabinoids (endocannabinoids). These G protein-coupled receptors play an important role in many processes, including metabolic regulation, craving, pain, anxiety, bone growth, and immune function. Cannabinoid receptors can be engaged directly by agonists or antagonists, or indirectly by manipulating endocannabinoid metabolism. In the past several years, it has become apparent from preclinical studies that therapies either directly or indirectly influencing cannabinoid receptors might be clinically useful. This review considers the components of the endocannabinoid system and discusses some of the most promising endocannabinoid-based therapies. SN - 0362-1642 UR - https://www.unboundmedicine.com/medline/citation/16402900/Cannabinoid_receptors_as_therapeutic_targets_ L2 - http://arjournals.annualreviews.org/doi/full/10.1146/annurev.pharmtox.46.120604.141254?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -